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Abstract
Background: Postpartum hemorrhage (PPH) remains a major killer of women worldwide. Standard uterotonic
treatments used to control postpartum bleeding do not always work and are not always available. Misoprostol's
potential as a treatment option for PPH is increasingly known, but its use remains ad hoc and available evidence
does not support the safety or efficacy of one particular regimen. This study aimed to determine the adjunct
benefit of misoprostol when combined with standard oxytocics for PPH treatment.
Methods: A randomized controlled trial was conducted in four Karachi hospitals from December 2005 – April
2007 to assess the benefit of a 600 mcg dose of misoprostol given sublingually in addition to standard oxytocics
for postpartum hemorrhage treatment. Consenting women had their blood loss measured after normal vaginal
delivery and were enrolled in the study after losing more than 500 ml of blood. Women were randomly assigned
to receive either 600 mcg sublingual misoprostol or matching placebo in addition to standard PPH treatment with
injectable oxytocics. Both women and providers were blinded to the treatment assignment. Blood loss was
collected until active bleeding stopped and for a minimum of one hour after PPH diagnosis. Total blood loss,
hemoglobin measures, and treatment outcomes were recorded for all participants.
Results: Due to a much lower rate of PPH than expected (1.2%), only sixty-one patients were diagnosed and
treated for their PPH in this study, and we were therefore unable to measure statistical significance in any of the
primary endpoints. The addition of 600 mcg sublingual misoprostol to standard PPH treatments does, however,
suggest a trend in reduced postpartum blood loss, a smaller drop in postpartum hemoglobin, and need for fewer
additional interventions. Women who bled less overall had a significantly smaller drop in hemoglobin and received
fewer additional interventions. There were no hysterectomies or maternal deaths among study participants. The
rate of transient shivering and fever was significantly higher among women receiving misoprostol
Conclusion: A 600 mcg dose of misoprostol given sublingually shows promise as an adjunct treatment for PPH
and its use should continue to be explored for its life-saving potential in the care of women experiencing PPH.
Trial Registration: Clinical trials.gov, Registry No. NCT00116480
Published: 21 August 2008
BMC Pregnancy and Childbirth 2008, 8:40 doi:10.1186/1471-2393-8-40
Received: 13 May 2008
Accepted: 21 August 2008
This article is available from: http://www.biomedcentral.com/1471-2393/8/40
© 2008 Zuberi et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Pregnancy and Childbirth 2008, 8:40 http://www.biomedcentral.com/1471-2393/8/40
Page 2 of 8
(page number not for citation purposes)
Background
Excessive bleeding after childbirth, the leading cause of
maternal deaths worldwide, has received international
attention among medical and research communities for
decades. A crucial component in the treatment of PPH
resulting from atonic uterus is the administration of
injectable uterotonics. The most commonly used agents
in hospital-based settings are oxytocin and/or
ergometrine. Additional medical and surgical interven-
tions, beyond the administration of conventional uterot-
onics, have also been investigated as alternative and
adjuvant therapy options for postpartum bleeding. The
off-label use of misoprostol, a prostaglandin E1 analogue,
has entered into clinical practice for this indication
because of its strong uterotonic properties, and its ease in
oral administration, stability at ambient temperatures,
wide availability, and low cost. A 600 mcg dose of oral
misoprostol has been shown safe and effective in prevent-
ing PPH [1]. Misoprostol is less effective than injectable
oxytocin, and it has therefore been recommended only for
prevention of PPH in settings where injectable conven-
tional uterotonics are not available [2]. No misoprostol
regimens have been proven for routine use as a stand
alone or adjunct treatment for postpartum hemorrhage.
To date, only three small randomized controlled trials
(RCT) of misoprostol for the treatment of PPH have been
conducted [3-5]. The first RCT compared use of misopros-
tol (800 mcg rectally) as a first-line treatment with stand-
ard oxytocics; the latter two placebo-controlled trials
assessed the additive effect of misoprostol when used in
conjunction with standard oxytocics. The misoprostol reg-
imens in these RCTs ranged from 600 to 1000 mcg and
the routes of administration varied (oral, sublingual, and
rectal). A trend in blood loss reduction in the misoprostol
arms was shown, but the trials were not adequately pow-
ered to produce any statistically significant findings. A
meta-analysis of the combined data from the two pla-
cebo-controlled trials testing misoprostol as an adjunct
PPH treatment, however, does show a statistically signifi-
cant reduction of blood loss of 500 ml or more after treat-
ment [6,7]. Seven uncontrolled studies or case reports
have demonstrated misoprostol's strong uterotonic effect
in stopping bleeding when used as a last resort treatment
in hospital-based settings [8-14]. In community-based
settings, findings from an intervention trial, where Tanza-
nian traditional birth attendants were trained to adminis-
ter 1000 mcg of misoprostol rectally as first-line PPH
treatment, provided insight on the drug's potential role in
PPH care [15]. Despite the promising results for misopr-
ostol's therapeutic use as primary PPH treatment, as an
additional treatment to standard oxytocics or as a last
resort treatment option, the published RCTs have been
small and the regimens studied have varied greatly, mak-
ing it difficult to draw clear conclusions. A recent review
on misoprostol for PPH noted that the current available
evidence was insufficient to support the use of misopros-
tol for routine treatment of PPH [16]. In the absence of
large randomized controlled trials with conclusive results,
clinicians are left to decide on the best combination of
medical interventions to control postpartum bleeding.
In Pakistan, where PPH accounts for nearly 25% of mater-
nal deaths [17], anecdotal evidence suggests that misopr-
ostol is often used in hospital settings. However, in a
country where statistics on maternal health outcomes are
largely unavailable [18], the benefits and/or risks of using
misoprostol as an alternative or adjunct therapy for post-
partum hemorrhage remain unknown. To establish the
effectiveness of adding misoprostol to current treatment
regimens, a randomized controlled trial was conducted to
test a 600 mcg dose of sublingual misoprostol as an
adjunct treatment at four hospitals in Karachi, Pakistan.
The 600 mcg dose was selected for its demonstrated safety
and efficacy in previous PPH trials of its prophylactic oral
use, and the sublingual administration of misoprostol
was preferred for its rapid onset of action, prolonged dura-
tion, and greater bioavailability [6]. By testing the drug's
efficacy as an adjunct PPH treatment, this trial provides
insight on the potential of misoprostol to treat PPH more
effectively.
Methods
The purpose of this randomized controlled trial was to
ascertain whether 600 mcg of misoprostol taken sublin-
gually provides an additional benefit to a standard oxy-
tocin regimen for treatment of PPH. The study had a
pragmatic approach with minimal interference in the cur-
rent routine management of delivery. Prior to trial com-
mencement, a meeting was jointly conducted with
representatives from the participating hospitals to docu-
ment routine PPH prevention and treatment protocols at
their facilities, and a management protocol was developed
to guide PPH treatment practices over the course of the
study. The trial was approved by the Ethical Review Com-
mittee at the Aga Khan University in Karachi.
The study began in December 2005, with the last woman
enrolled in April 2007 after 16 months of continuous
recruitment. The study aimed to enroll 900 women over
18 months at four hospitals in Karachi, Pakistan: The Aga
Khan University Hospital (AKUH) a large tertiary level
hospital; and three secondary level facilities within the
Aga Khan Network – Aga Khan Hospital for Women in
Karimabad District, Aga Khan Hospital for Women in
Garden District and Aga Khan Hospital for Women and
Children in Kharadar District. Each of these hospitals has
approximately 2,000 deliveries per year. Laboring women
were given detailed information on the study protocol
and invited to participate in the trial by trained hospitalBMC Pregnancy and Childbirth 2008, 8:40 http://www.biomedcentral.com/1471-2393/8/40
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staff. A consent form (available in English and Urdu) was
signed or thumb-printed by consenting women. Women
with cesarean-section, gestational age less than 28 weeks
at time of delivery, or not consenting were excluded from
the study.
All women underwent routine active management of the
third stage of labor with standard uterotonics, controlled
cord traction after delivery of baby, and gentle uterine
massage after delivery of the placenta. At the delivery of
the anterior shoulder of baby, one of two uterotonic regi-
mens was administered: intravenous 10 IU of oxytocin or
5 IU of oxytocin plus 0.4 mg of ergometrine given either
intramuscularly or intravenously. Immediately after deliv-
ery of the baby, blood loss was collected by placing a clean
fracture bedpan directly under the woman's buttocks for a
minimum of one hour. Markings were written onto the
bedpan to show when 500 ml had been reached. Women
losing less than 500 ml were not entered into the trial.
Women losing 500 ml or more were enrolled in the trial,
and a clean bedpan was placed underneath their buttocks
to collect blood lost after PPH diagnosis. A fresh, large
perineal pad with plastic backing was positioned just
below the bedpan to capture any spattering blood. Once
the delivery attendant considered active bleeding to have
stopped, the blood was transferred to a calibrated jar for
measurement.
All women with diagnosed PPH thought to be due to
inadequate uterine contraction, as per the provider's clin-
ical judgment, were promptly given IV oxytocin as routine
for PPH treatment. Women were reminded of their con-
sent to participate in the trial and a member of study team
gave each woman the pills in the next randomized study
envelope and instructed her to place the tablets under her
tongue, e.g. sublingually. Each study envelope contained
three tablets of either misoprostol (200 mcg × 3) (Gym-
iso, HRA Pharma, France) or matching placebo. All
women, providers, and investigators were blinded to the
treatment assignments. Simultaneous to PPH treatment
administration, blood collection was restarted with a
clean bedpan and fresh perineal pad placed underneath
the woman. Blood loss was then measured continuously
until active bleeding ceased – or for a minimum of one
hour. The additional blood loss after receiving PPH treat-
ment was transferred to a calibrated jug and sealed, and all
used gauzes and pads were counted and placed in a plastic
bag. The plastic bag was then weighed; however, accurate
use of the scales proved difficult, and these results could
not be verified. Therefore, in this paper we share the vali-
dated results of total volume of blood collected.
Based on previous studies, we estimated a 10% rate of
additional blood loss ≥ 500 ml [6] after receiving study
treatment in the oxytocin-misoprostol arm and a rate of
16% in the oxytocin-placebo arm. To detect a difference of
this size (one-sided test), we calculated that to achieve
80% power at p = 0.05, a sample size of 420 women in
each arm was needed. The sample was randomized in
blocks of ten, stratified by site, using a computer-gener-
ated random sequence provided by Gynuity Health
Projects, New York, where the code was kept. Data were
entered and cleaned in Epi Info (Epi Info, version 3.4.3).
The randomization code was concealed until all data were
entered and cleaned. Data analysis was conducted using
the Statistical Package for the Social Sciences, version 13.0
(SPSS, Chicago, IL, USA). Using SPSS, categorical data
were analyzed with chi-square tests and continuous data
with t tests.
The main study outcome was to determine if the addition
of misoprostol to standard PPH care reduces postpartum
bleeding. The primary endpoint was measured blood loss
≥ 500 mls after PPH treatment; secondary outcomes
included change in hemoglobin, side effects, need for
additional interventions including blood transfusion,
additional uterotonics, balloon tamponade, hysterec-
tomy, and mean blood loss. Hemoglobin levels were
measured pre-delivery upon entry into labor ward and
12–24 hours post-delivery by taking a finger prick and
using a Hemocue Hemoglobin machine (HemoCue AB,
Ängleholm, Sweden). Side effects were recorded by the
delivery attendant as they were observed or reported.
Blood loss was documented for women who consented
for the study but did not experience PPH. Regular moni-
toring and training of delivery ward staff continued
throughout duration of the trial.
Results
Blood loss following 5,171 vaginal deliveries was col-
lected at the four participating hospitals. The mean blood
loss and postpartum hemoglobin level were 150 ml and
11.2 g/dL, respectively. Sixty-one women (1.2%) were
diagnosed with PPH and randomized to receive either
oxytocin plus 600 mcg misoprostol sublingually (n = 29)
or oxytocin plus matching placebo (n = 32). Deviations in
study protocol occurred among two women randomized
to the misoprostol arm. In one protocol deviation, the
patient was given only 400 mcg of study medication
because the delivery ward staff questioned whether her
bleeding might be due to episiotomy. The second proto-
col deviation involved a woman whose blood mistakenly
was not collected by hospital staff. Table 1 details the
baseline demographic and delivery characteristics of all
study participants (n = 61). There were no significant dif-
ferences between women in the two groups.
All women had their third stage of labor actively managed
as per standard hospital protocol. There were no statistical
differences in the amount and route of prophylactic oxy-BMC Pregnancy and Childbirth 2008, 8:40 http://www.biomedcentral.com/1471-2393/8/40
Page 4 of 8
(page number not for citation purposes)
tocin administered between the two study groups. All
women received oxytocin prophylaxis at the delivery of
anterior shoulder of baby (IV administration 88.5%; IM
administration 11.5%). The prophylactic use of
ergometrine in addition to oxytocin was also standard
practice at two of the four sites. In half of the deliveries
(equally distributed across study arms), ergometrine was
administered prophylactically (IV administration 60.0%;
IM administration 40.0%) in conjunction with oxytocin.
On average, PPH was diagnosed 35 minutes following
delivery after losing an average of 655 ml (± 163 ml) of
blood, at which time PPH treatment was administered.
There were no differences in the dose, route or choice of
standard uterotonics given for PPH treatment between the
two study groups. Intravenous oxytocin (bolus 5–30 units
and infusion 10–80 units in 500–1000 ml saline) and
ergometrine up to 0.4 mg i.v. were initial treatment meas-
ures. Oxytocin infusion was given for all PPH cases; two-
thirds were given intravenous oxytocin in bolus; and only
one-third of cases received 0.2–0.4 mg ergometrine i.v. Six
cases (four in the misoprostol group and two in the pla-
cebo group) were given an additional dose of 200–400
mcg misoprostol either rectally or sublingually. Prostag-
landin alpha F-2 was administered to one woman in mis-
oprostol group and three in the placebo group.
There were no problems reported with sublingual admin-
istration of study medication. The study outcomes are
summarized in Table 2. Due to the much lower than
expected PPH rate, the intended sample size was not
reached. Postpartum blood loss, drop in hemoglobin, and
use of additional interventions (blood transfusion, uter-
ine packing, and balloon tamponade) were lower in mis-
oprostol group, but did not reach statistical significance.
Fewer women in the misoprostol arm received i.v. fluids
amounting to greater than 1000 ml (p = .056). Among
those women receiving additional interventions (twelve
in the misoprostol group; nineteen in the placebo group),
total measured blood loss was significantly higher (940 ±
341 ml, p = .028) compared with women (n = 29) who
did not receive any additional intervention beyond stand-
ard treatment (780 ± 176 ml). Similarly, drop in postpar-
tum hemoglobin was significantly higher among women
requiring additional interventions (2.5 g/dL (± 1.5) vs. 1.7
g/dL (± 0.9); p = .022). There were no hysterectomies or
maternal deaths among study participants.
Shivering and fever were more commonly reported in the
misoprostol group. All other side effects were minimal
(Table 3). Transient shivering was experienced by 51.7%
of women receiving misoprostol compared with 6.2% in
placebo group. The incidence of fever followed similar
Table 1: Baseline characteristics among women treated for PPH
misoprostol placebo
n = 29 n = 32 RR [95% CI] or p-value
Age (years) mean ± sd 25 ± 5 26 ± 4 p = .291
Parity %(n)
0 62.1 (18) 40.6 (13) 1.53 [.92, 2.54]
1–3 31.0 (9) 50.0 (16)
4–8 6.9 (2) 9.4 (3)
Outcome of this delivery %(n)
Singleton, alive 93.1 (27) 96.9 (31) .96 [.85, 1.08]
Singleton, still birth 3.4 (1) --
Twins, both alive 3.4 (1) 3.7 (1)
Episiotomy %(n) 75.9 (22) 68.8 (22) 1.10 [.81, 1.51]
Manual removal of placenta done %(n) 6.9 (2) 12.5 (4) .55 [.11, 2.79]
Placental delivery within 5 minutes %(n) 62.1 (18) 78.1 (25) .79 [.57,1.11]
Pre-delivery hemoglobin (g/dL)
mean ± sd 11.1 ± 1.0 10.9 ± 1.1 p = .502
range 9.1 – 13.5 8.7 – 13.0
Measured blood loss at diagnosis (ml)
mean ± sd 640 ± 139 669 ± 184^ p = .492
range 400 – 1000 500 – 1000
Time to diagnosis (minutes)
mean ± sd 37 ± 29 33 ± 24 p = .584
range 5 – 122 5 – 100
Use of oxytocics prior to study treatment %(n) 100 (29) 100 (32) 1.0
Use of oxytocics after study treatment %(n) 100 (29) 100 (32) 1.0
^ There is one outlier excluded in which the woman was diagnosed after losing 1,750 ml.BMC Pregnancy and Childbirth 2008, 8:40 http://www.biomedcentral.com/1471-2393/8/40
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pattern to that of shivering. Eleven women (37.9%) in the
misoprostol group experienced an elevated temperature
of ≥ 37.5°C (≥ 99.5°F) compared with only three women
(9.4%) in the placebo group. Three women receiving mis-
oprostol characterized their fever as being severe. There
was one case of high fever reported in the misoprostol
group in which temperature at one hour post-treatment
measured 40.1°C (104.2°F). There were no reports of
severe side effects resulting in prolonged hospitalization
or other adverse events in misoprostol group and all
women made a full recovery.
Discussion
The purpose of this trial was to explore whether 600 mcg
sublingual misoprostol offers any additional benefit
when added simultaneously to conventional methods for
the treatment of primary postpartum bleeding. Although
the study findings reported here are consistent with the
two placebo-controlled trials on adjunct use of misopros-
tol [4,5], we were unable to measure statistical signifi-
cance in our primary endpoints due to a much lower rate
of PPH than expected. Our findings suggest a trend in
reduced postpartum blood loss, smaller drop in postpar-
tum hemoglobin, and fewer additional interventions
among women treated with misoprostol in addition to
standard oxytocics.
The use of misoprostol was not associated with a signifi-
cant reduction in any of the pre-specified primary out-
come measures in this study. However, the relative risk
reduction of 41% of blood loss ≥ 500 ml after treatment
(RR 0.59 95% CI [0.12, 2.99]) is similar to the two hospi-
tal-based placebo-controlled trials conducted in South
Africa (RR 0.56 95% CI [0.21, 1.46]) and the Gambia (RR
0.58, 95% CI [0.32, 1.06]) [6]. Indeed, a combined anal-
ysis of results from this trial and the two placebo-control-
led trials on adjunct use of misoprostol [4,5] confirms
that misoprostol use is associated with a significant reduc-
tion of blood loss of ≥ 500 ml following treatment (RR
0.58, 95% CI [0.35, 0.95], p = .029). This confers with
results from other recent meta-analyses [2,6,7].
Our study findings on measured postpartum blood loss
also highlight the clinical importance of a reduction of
blood loss following PPH treatment. Women who bled
less overall had a significantly smaller drop in hemo-
globin and did not require additional interventions, such
as blood transfusion, balloon tamponade, or uterine
packing, to manage their postpartum bleeding. In con-
trast, women who had a significantly higher total blood
loss were more likely to be given additional interventions
and experience a larger drop in postpartum hemoglobin.
A reduction in blood loss reduces need for more invasive
Table 2: Outcomes after receiving study treatment
misoprostol placebo
n = 29 n = 32 RR [95% CI] or p-value
Postpartum blood loss after study treatment
(n = 27) ^ (n = 32)
Total blood loss post-treatment (ml)
mean ± sd 175 ± 168 187 ± 207 p = .809
Range 10–700 10–900
Blood loss ≥ 500 ml post-treatment %(n) 7.4 (2) 12.5 (4) .59 [.12, 2.99]
Postpartum hemoglobin measures
Post-delivery Hb
mean ± sd 9.0 ± 1.4 8.7 ± 1.2 p = .291
range 5.9 – 11.3 5.9 – 10.2
Drop in Hb
mean ± sd 2.0 ± 1.1 2.2 ± 1.4 p = .614
range 0.4 – 4.2 0.1 – 5.1
Postpartum Hb ≥ 2 g/dL lower than pre-delivery Hb %(n) 41.4 (12) 56.3 (18) .74 [.43, 1.25]
Additional interventions
Amount of IV fluids given
500–1000 ml 75.9 (22) 53.1 (17)
> 1000 ml 24.1 (7) 46.9 (15) .51 [.24, 1.08]
Blood transfusion %(n) 17.2 (5) 18.8 (6) .92 [.31, 2.69]
Uterine packing %(n) 6.9 (2) 18.8 (6) .37 [.08, 1.68]
Balloon tamponade %(n) 0.0 (0) 3.1 (1) .00 [.00, 43.0]
Referrals for additional PPH care %(n) 3.4 (1) 3.2 (1) 1.1 [.07, 16.9]
^ Two cases in the misoprostol arm have incomplete blood loss measurements and were excluded from analysis of measured postpartum blood 
loss.BMC Pregnancy and Childbirth 2008, 8:40 http://www.biomedcentral.com/1471-2393/8/40
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procedures, results in a smaller change in postpartum
hemoglobin, and as a result, may prevent more severe
maternal morbidity experienced by recently delivered
mothers. Based on the trends in blood loss we see among
women in our study given misoprostol in addition to
standard oxytocics for their PPH treatment, the adjunct
use of misoprostol shows great potential in improving
women's health outcomes after experiencing this obstetri-
cal complication.
As found in previous studies on misoprostol, use of the
drug was significantly associated with fever and shivering.
These effects, however, were described as transient and
did not result in any additional complication to the
women. Within the literature on misoprostol as adjunct
treatment, a total of three cases of high fever ≥ 40.0°C (≥
104.0°F) have been reported following a 1000 mcg dose
of misoprostol (400 mcg sublingually + 400 mcg rectally
+ 200 mcg orally) [4]. This study had one case of temper-
ature over 40.0°C in the misoprostol group. Delivery
ward staff should be trained to recognize and manage
cases of severe shivering and high fever to ensure proper
care of the patient.
Great efforts were taken to standardize PPH care within
and across the participating hospitals. Representatives
from the hospitals reviewed their PPH management poli-
cies and developed a document to guide their treatment
practices over the course of the study and thereafter.
Despite efforts to standardize PPH care, there still existed
variation in the pharmacological agents/regimens used,
especially in the administration of second- or third-line
therapies. For instance, six patients were given an addi-
tional dose of misoprostol beyond initial treatments.
Table 3: Side effects after receiving study treatment
misoprostol placebo
n = 29 n = 32 RR [95% CI] or p-value
Nausea %(n)
none 93.1 (27) 93.8 (30) .99 [.87, 1.13]
mild or moderate 6.9 (2) 6.3 (2)
severe -- --
Vomiting %(n)
none 93.1 (27) 96.9 (31) .96 [.85, 1.08]
mild or moderate 6.9 (2) --
severe -- 3.1 (1)
Diarrhea %(n)
none 100 (29) 100 (32) 1.0
mild or moderate -- --
severe -- --
Fainting %(n)
none 100 (29) 96.9 (31) 1.03 [.97, 1.10]
mild or moderate -- 3.1 (1)
severe -- --
Fatigue %(n)
none 100 (29) 100 (32) 1.0
mild or moderate -- --
severe -- --
Headache %(n)
none 93.1 (27) 100 (32) .93 [.84, 1.03]
mild or moderate 6.9 (2) --
severe -- --
Shivering %(n)
none 48.3 (14) 93.8 (30)
mild or moderate 37.9 (11) 6.2 (2) 8.28 [2.1. 33.1]
severe 13.8 (4) --
Fever %(n)
none 48.3 (14) 90.6 (29)
mild or moderate 41.4 (12) 9.4 (3) 5.52 [1.8, 17.1]
severe 10.3 (3) --
Temperature at 1 hour (Celsius)
mean ± sd 37.4 ± .94 37.0 ± .35 p = .022
range 36.2 – 40.1 36.3 – 37.8BMC Pregnancy and Childbirth 2008, 8:40 http://www.biomedcentral.com/1471-2393/8/40
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Although the hospitals in this study had policies caution-
ing against the use of prostaglandins due to lack of evi-
dence, providers still relied on their use as a therapy
options.
Irrespective of the variability in PPH practices, a low rate
of PPH < 2% across the four participating hospitals was
demonstrated in this study. This rate of PPH was validated
using an objective measurement protocol with marked
bedpan in over 5,000 normal vaginal deliveries. Studies
on postpartum hemorrhage often find that the incidence
of PPH is underreported in settings prior to objective
measurement of postpartum blood loss [19-22], however
this study shows just the opposite with a measured PPH
rate of 1.2%. According to the 2000 Cochrane Review, the
rate of PPH ≥ 500 ml is roughly 5% for women receiving
prophylactic uterotonics and 12% for those not receiving
uterotonics prophylactically [23]. Importantly, only two
of the four studies included in the review specified the use
of an objective blood measurement technique. In general,
there is wide variability in reported PPH rates in the liter-
ature. As Soriano and colleagues note, PPH incidence ≥
500 ml has been reported at 1.0%, 5.0%, 7.2%, and
14.5% in studies comparing oxytocin-ergometrine and
oxytocin alone in the third stage of labor [24]. This study,
using objective measurement of postpartum blood loss,
confirms that a very low rate of PPH can be achieved in
hospital settings following the routine practice of active
management of the third stage of labor. At the same time,
the low rate of PPH in this study demonstrates the diffi-
culty in conducting hospital-based studies on relatively
rare, but clinically important obstetrical complications.
The objective assessment of postpartum bleeding pro-
vided a valuable, initially unexpected, insight into the
diagnosis and management of PPH in the four Karachi
hospitals. Individual exit interviews with study staff
revealed that they believed the use of the bedpan had cor-
rected their "over"-estimation of postpartum blood loss.
Both doctors and nurses explained that previously they
had overestimated postpartum blood loss, resulting in
misdiagnosis of PPH, unnecessary treatments, and pro-
longed hospitalization. During the study, staff was trained
to diagnose PPH at 500 ml using the bedpan for objective
assessment. However, PPH was diagnosed, on average,
after losing nearly 650 ml, which suggests that the use of
the bedpan did not lead to more prompt diagnosis at 500
ml. The timing of diagnosis, which commonly occurred
around 30 minutes after delivery, also provided valuable
insight on the duration of close-monitoring necessary
during the postpartum period for all recently delivered
mothers. Objective measures using the bedpan and
Hemocue apparatus also verified that those women with
greater postpartum bleeding and larger decline in postpar-
tum hemoglobin were commonly provided with addi-
tional interventions beyond standard uterotonic
treatments to control their bleeding. The use of the bed-
pan proved to be a valuable tool for educating delivery
ward staff over the course of the study on the diagnosis
and management of postpartum hemorrhage, but the
value of its continued use outside a clinical trial is not yet
apparent.
Conclusion
Due to the logistical complexities of managing postpar-
tum hemorrhage, this obstetrical complication continues
to threaten women's lives, especially in facilities short-
staffed or lacking uterotonics and protocols to manage
PPH safely and effectively. It has been advocated that mis-
oprostol should be available in community-based settings
with limited access to conventional injectable uterotonics.
This study suggests that misoprostol may also have an
important role to play in hospital settings and its adjunct
use should continue to be explored for its potential in
quickly, safely, and effectively controlling postpartum
bleeding, averting recourse to more invasive procedures,
and preventing more severe maternal morbidity.
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